Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Will Have Day In Court With Roche

This article was originally published in The Pink Sheet Daily

Executive Summary

The company also reports that sales of its TNF inhibitor Enbrel are “not meeting expectations.”

You may also be interested in...



Roche’s Mircera BLA Set Back Three Months For FDA Review Of New Data

Delay could affect Amgen’s timeline for a potential filing of a preliminary injunction in its case against Roche, slated for trial in September.

Roche’s Mircera BLA Set Back Three Months For FDA Review Of New Data

Delay could affect Amgen’s timeline for a potential filing of a preliminary injunction in its case against Roche, slated for trial in September.

Amgen’s “Anticompetitive Scheme” On EPO Should Be Invalidated By Court, Roche Says

Roche seeks monetary damages and a ruling that Amgen’s conduct regarding its “monopoly” on erythropoietin is unlawful in court filing.

Related Content

Topics

UsernamePublicRestriction

Register

PS063251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel